Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion–Dependent Patients With Myelodysplastic SyndromeAlan F. List, Emmanuel C. Besa, Carole Paley et al.|Journal of Clinical Oncology|2012Cited by 175
Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromesAmer M. Zeidan, Amy J. Davidoff, Franklin Hendrick et al.|Journal of Comparative Effectiveness Research|2015Cited by 45
Iron Chelation with Deferasirox (Exjade®) Improves Iron Burden in Patients with Myelodysplastic Syndromes (MDS)Alan F. List, Emmanuel C. Besa, John Feigert et al.|Blood|2008Cited by 31